Kenneth T. Luu

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

Luis Fayad, Fritz Offner, Mitchell R. Smith et al. · Journal of Clinical Oncology · 2013 · 153 citations · Full text

A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition

Kenneth T. Luu, Simon Bergqvist, Enhong Chen et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 80 citations

Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations

Kenneth T. Luu, Daniel A. Norris, Rudy Gunawan et al. · The Journal of Clinical Pharmacology · 2017 · 53 citations

Pharmacokinetics and Metabolism of [ ¹⁴ C]Viramidine in Rats and Cynomolgus Monkeys

Chin‐Chung Lin, Kenneth T. Luu, David Lourenco et al. · Antimicrobial Agents and Chemotherapy · 2003 · 22 citations · Full text

Total Body Clearances, Pharmacokinetic Modeling, Cynomolgus Monkeys +13

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Daniel J. DeAngelo, Wendy Stock, Andrei R. Shustov et al. · Blood · 2013 · 22 citations